Quoin pharmaceuticals announces initial positive clinical data for qrx003 from pediatric peeling skin syndrome study

Ashburn, va., may 14, 2025 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive initial clinical data from its ongoing investigator pediatric peeling skin syndrome clinical study.
QNRX Ratings Summary
QNRX Quant Ranking